Mavitalon

Diltiazem Hydrochloride, the active ingredient in Mavitalon, is a calcium channel blocker presented as an oral tablet for systemic use. It is employed to lower elevated blood pressure and to relieve chest pain associated with chronic stable angina in adult patients.

GNH USA supplies Mavitalon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diltiazem Hydrochloride acts on the cardiovascular system to manage pressure‑related and ischemic conditions. - Hypertension: helps lower elevated arterial pressure in adult patients. - Chronic stable angina: reduces the frequency and severity of chest pain episodes. - Atrial flutter: assists in controlling ventricular rate during episodes of atrial flutter.

Common Side Effects: - Headache: mild to moderate discomfort often occurring early in therapy. - Flushing: transient warmth and redness, especially of the face. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, particularly when standing quickly.

Serious or Rare Side Effects: - Bradycardia: abnormally slow heart rate that may require medical attention. - Severe hypotension: marked drop in blood pressure causing faintness or shock. - Heart block: impairment of electrical conduction through the heart.

Before initiating therapy, consider the following precautions: - Monitor blood pressure: check regularly to ensure therapeutic response. - Assess cardiac function: evaluate for existing conduction abnormalities. - Use caution in hepatic impairment: dose adjustments may be needed. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Review concomitant beta‑blocker therapy: increased risk of bradycardia. - Store at room temperature: keep in the original pack, protect from moisture.

Diltiazem Hydrochloride may interact with several medicines. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise diltiazem levels. - Concurrent beta‑blockers: may cause excessive bradycardia. - Digoxin: increased risk of digoxin toxicity. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce diltiazem effectiveness. - Macrolide antibiotics (e.g., erythromycin): may modestly increase plasma concentrations.